Thrailkill K - Search Results

1

A multicomponent motivational intervention to improve adherence among adolescents with poorly controlled type 1 diabetes: a pilot study.

Stanger C, Ryan SR, Delhey LM, Thrailkill K, Li Z, Li Z, Budney AJ. Stanger C, et al. Among authors: thrailkill k. J Pediatr Psychol. 2013 Jul;38(6):629-37. doi: 10.1093/jpepsy/jst032. Epub 2013 May 22. J Pediatr Psychol. 2013. PMID: 23699750 Free PMC article.

2

Insulin pump therapy started at the time of diagnosis: effects on glycemic control and pancreatic β-cell function in type 1 diabetes.

Thrailkill KM, Moreau CS, Swearingen C, Rettiganti M, Edwards K, Morales AE, Kemp SF, Frindik JP, Fowlkes JL. Thrailkill KM, et al. Diabetes Technol Ther. 2011 Oct;13(10):1023-30. doi: 10.1089/dia.2011.0085. Epub 2011 Jun 30. Diabetes Technol Ther. 2011. PMID: 21718094 Clinical Trial.

3

Matrix metalloproteinase-2 dysregulation in type 1 diabetes.

Thrailkill KM, Bunn RC, Moreau CS, Cockrell GE, Simpson PM, Coleman HN, Frindik JP, Kemp SF, Fowlkes JL. Thrailkill KM, et al. Diabetes Care. 2007 Sep;30(9):2321-6. doi: 10.2337/dc07-0162. Epub 2007 Jun 11. Diabetes Care. 2007. PMID: 17563344 Free PMC article. Clinical Trial.

4

Stimulant medication use and response to growth hormone therapy: an NCGS database analysis.

Frindik JP, Morales A, Fowlkes J, Kemp S, Thrailkill K, Lippe B, Dana K. Frindik JP, et al. Among authors: thrailkill k. Horm Res. 2009;72(3):160-6. doi: 10.1159/000232491. Epub 2009 Sep 1. Horm Res. 2009. PMID: 19729947 Clinical Trial.

5

Bone formation is impaired in a model of type 1 diabetes.

Thrailkill KM, Liu L, Wahl EC, Bunn RC, Perrien DS, Cockrell GE, Skinner RA, Hogue WR, Carver AA, Fowlkes JL, Aronson J, Lumpkin CK Jr. Thrailkill KM, et al. Diabetes. 2005 Oct;54(10):2875-81. doi: 10.2337/diabetes.54.10.2875. Diabetes. 2005. PMID: 16186388

6

Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues.

Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Thrailkill KM, et al. Am J Physiol Endocrinol Metab. 2005 Nov;289(5):E735-45. doi: 10.1152/ajpendo.00159.2005. Am J Physiol Endocrinol Metab. 2005. PMID: 16215165 Free PMC article. Review.

7

Investigational agents for the treatment of growth hormone-insensitivity syndrome.

Kemp SF, Thrailkill KM. Kemp SF, et al. Expert Opin Investig Drugs. 2006 Apr;15(4):409-15. doi: 10.1517/13543784.15.4.409. Expert Opin Investig Drugs. 2006. PMID: 16548790 Review.

8

Efficacy and safety of mecasermin rinfabate.

Kemp SF, Fowlkes JL, Thrailkill KM. Kemp SF, et al. Expert Opin Biol Ther. 2006 May;6(5):533-8. doi: 10.1517/14712598.6.5.533. Expert Opin Biol Ther. 2006. PMID: 16610982

9

Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic multiligand receptors megalin and cubilin.

Thrailkill KM, Nimmo T, Bunn RC, Cockrell GE, Moreau CS, Mackintosh S, Edmondson RD, Fowlkes JL. Thrailkill KM, et al. Diabetes Care. 2009 Jul;32(7):1266-8. doi: 10.2337/dc09-0112. Epub 2009 Apr 14. Diabetes Care. 2009. PMID: 19366958 Free PMC article.

10

Enhanced excretion of vitamin D binding protein in type 1 diabetes: a role in vitamin D deficiency?

Thrailkill KM, Jo CH, Cockrell GE, Moreau CS, Fowlkes JL. Thrailkill KM, et al. J Clin Endocrinol Metab. 2011 Jan;96(1):142-9. doi: 10.1210/jc.2010-0980. Epub 2010 Oct 13. J Clin Endocrinol Metab. 2011. PMID: 20943786 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page